Opendata, web and dolomites

SingCelCD SIGNED

Single Cell approaches for the study of oncogenic processes during coeliac disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SingCelCD" data sheet

The following table provides information about the project.

Coordinator
IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION 

Organization address
address: 24 BD DU MONTPARNASSE
city: PARIS 15
postcode: 75015
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 196˙707 €
 EC max contribution 196˙707 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION FR (PARIS 15) coordinator 196˙707.00

Map

 Project objective

Coeliac disease is a chronic autoimmune-like enteropathy induced by dietary gluten in 0.5-2% Europeans. A rare but specific complication is the onset of invasive enteropathy-associated lymphomas. The host laboratory has demonstrated that in approximately 70% of CD patients, invasive lymphomas are preceded by a clonal low-grade intraepithelial lymphoproliferation, usually called type II refractory CD (RCDII). I intend to take advantage of my experience in cellular immunology and single-cell analyses: 1- to analyse the peri-tumor microenvironment and search for anti-tumoral T cell response in RCDII; and 2- to analyse the functional intra-clonal heterogeneity among RCDII malignant cells. The results should provide further insight into the mechanisms, which control disease progression and will help us to assess therapeutic strategies. This project will complete and extend the on-going genomic analysis of lymphomas complicating CD. It will notably help to assess if the JAK1/STAT3 pathway is a pertinent therapeutic target and the possible interest of checkpoint inhibitors. To achieve the aims of the innovative translational project, I will integrate one of the European leader research center in genetic diseases, giving me the opportunity to gain experience in translational immunology and human genetics, as well as to reinforce my expertise in cutting-edge single cell technologies and bioinformatics. Overall this project represents a unique stepping-stone to complete my training in pathophysiology and establish collaborations, which should put me in excellent position to establish as an independent researcher.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SINGCELCD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SINGCELCD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PATH (2019)

Preservation and Adaptation in Turkish as a Heritage Language (PATH) - A Natural Language Laboratory in a Small Dutch Town

Read More  

TRACE-AD (2019)

Tracking the Effects of Amyloid and Tau Pathology on Brain Systems and Cognition in Early Alzheimer’s Disease

Read More  

LiquidEff (2019)

LiquidEff: Algebraic Foundations for Liquid Effects

Read More